AB 245
Alternative Names: AB-245Latest Information Update: 28 Nov 2023
At a glance
- Originator Angiocrine Bioscience
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Oct 2019 Preclinical trials in Autoimmune disorders in USA (Parenteral) (Angiocrine Bioscience pipeline, October 2019)